CeriBell (NASDAQ:CBLL) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

CeriBell (NASDAQ:CBLL) posted its quarterly earnings results on Tuesday. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04), FiscalAI reports. CeriBell had a negative return on equity of 50.37% and a negative net margin of 67.96%. The firm had revenue of $29.34 million during the quarter, compared to analyst estimates of $29.18 million.

Here are the key takeaways from CeriBell’s conference call:

• Q3 revenue rose 30% year over year to $29.3 million, supported by record additions of 35 hospitals and a total of 747 active accounts. Usage per account increased at a double-digit rate, driven by department expansion, provider engagement, and protocolization.
• The company launched its delirium monitoring solution commercially after a successful pilot that produced higher headband utilization and reported improvements in clinical decision-making. Management expects the offering to expand existing-account usage initially, although the rollout will be gradual and the product is being provided as a software upgrade without an incremental subscription fee.
• CeriBell received FDA 510(k) clearance for quantitative EEG trending and amplitude-integrated EEG analysis, with cloud-based releases planned for 2027. It also unveiled the Omni platform, which combines seizure, delirium, video, continuous monitoring, EKG compatibility, and additional EEG functionality, with a limited market release underway and a broader launch expected in 2027.
• Operating expenses increased 36% year over year to $46.9 million, contributing to a quarterly net loss of $21.4 million versus $13.5 million a year earlier. Adjusted EBITDA loss also widened to $12.1 million as the company continued investing in sales infrastructure, research and development, and new product launches.
• CeriBell raised the low end of its 2026 revenue outlook to $115 million-$117 million, representing 29%-31% growth, while maintaining the high end. The guidance excludes material contributions from neonatal, pediatric, and delirium products, which management expects to contribute more meaningfully in 2027; cash and marketable securities totaled $117.5 million at quarter-end.

CeriBell Stock Down 3.1%

CeriBell stock traded down $0.85 during trading hours on Thursday, hitting $26.54. The company had a trading volume of 173,664 shares, compared to its average volume of 369,029. The firm’s fifty day moving average is $25.13 and its 200-day moving average is $20.87. The firm has a market capitalization of $1.02 billion, a P/E ratio of -13.74 and a beta of 0.86. CeriBell has a fifty-two week low of $11.27 and a fifty-two week high of $28.89. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79.

Insider Buying and Selling at CeriBell

In other news, Director Joseph Taylor sold 13,095 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $23.40, for a total transaction of $306,423.00. Following the completion of the sale, the director directly owned 48,478 shares of the company’s stock, valued at $1,134,385.20. This trade represents a 21.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CTO Raymond Woo sold 4,887 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $24.33, for a total value of $118,900.71. Following the completion of the sale, the chief technology officer directly owned 203,118 shares of the company’s stock, valued at approximately $4,941,860.94. The trade was a 2.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 179,792 shares of company stock worth $4,444,748 over the last 90 days. 17.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

CBLL has been the subject of several analyst reports. BTIG Research reiterated a “buy” rating on shares of CeriBell in a research report on Wednesday. Barclays upgraded CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Canaccord Genuity Group lifted their target price on CeriBell from $26.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday. TD Cowen boosted their price target on CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $29.00 price objective on shares of CeriBell in a report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, CeriBell presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.25.

CeriBell Company Profile

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.